BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borba HH, Wiens A, Steimbach LM, Perlin CM, Tonin FS, Pedroso ML, Fernandez-Llimos F, Pontarolo R. Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. Eur J Clin Pharmacol 2017;73:1-14. [PMID: 27757504 DOI: 10.1007/s00228-016-2146-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Chan NS, Tam AW, Hung IFN, Chan EW. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801-1809. [PMID: 28516201 DOI: 10.1007/s10096-017-2995-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
2 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Ippolito G, Zumla A, Lanini S. Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C? Clin Microbiol Infect 2018;24:328-31. [PMID: 29326009 DOI: 10.1016/j.cmi.2018.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget 2017;8:72700-13. [PMID: 29069819 DOI: 10.18632/oncotarget.20282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]